Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Multiple-Dose, Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children 4 to 12 Years of Age

NCT04987762 is registered in ClinicalTrials.gov with Purdue Pharma LP as lead sponsor.

NCT NCT04987762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04987762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Multiple-Dose, Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children 4 to 12 Years of Age
Lead sponsor
Purdue Pharma LP
Phase
Phase 4
Overall status
Terminated
Start date
August 3, 2021
Completion date
April 27, 2022
Enrollment
103 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit/hyperactivity disorder